Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold.

Thursday, Sep 4, 2025 8:28 am ET1min read
Dare Bioscience, Inc. rose 4.37% in premarket trading, following Maxim's upgrade of the company to "Buy" from "Hold." The upgrade reflects the company's commitment to advancing products for women's health, including its FDA-approved product XACIATO and its various clinical and pre-clinical stage programs.

Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold.

Comments



Add a public comment...
No comments

No comments yet